The role of systemic cytotoxic therapy for prostate cancer

BJU International

Volumn 103, Issue 1, 2009, Pages 8-17

  Chang, Sam S ^b   Kibel, Adam S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti neoplastic agents; Drug therapy; Prostatic neoplasms

Indexed keywords

AMINOGLUTETHIMIDE; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CALCITRIOL; CAPECITABINE; CARBOPLATIN; CORTICOSTEROID; CYPROTERONE ACETATE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GONADORELIN AGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SATRAPLATIN; TAXANE DERIVATIVE; THALIDOMIDE; UNINDEXED DRUG; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; BEDTIME DOSAGE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 57649213265     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08256.x     Document Type: Review

References (97)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004 101 : 3 27
3. Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005 97 : 1407 27
4. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
6. Crawford D. Changing concepts in the management of advanced prostate cancer. Urology 1994 44 (Suppl. 1 67 74
7. Moul JW. The evolving definition of advanced prostate cancer. Rev Urol 2004 6 (Suppl. 8 S10 7
8. Moul JW, Wu H, Sun L et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002 132 : 213 9
9. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 1999 17 : 3461 7
10. Eisenberger MA, Carducci MA. Chemotherapy for hormone-resistant prostate cancer. In Richer S, Campbell's Urology, 8th edn. Philadelphia : WB Saunders, 2002 : 4
11. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004 171 : 1525 8
12. Huggins C, Hodges C. Studies on prostate cancer. I. The effect of castration of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 1 : 93 7
13. Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006 176 : S72 5
14. Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998 159 : 149 53
15. Kucuk O, Fisher E, Moinpour CM et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001 58 : 53 8
16. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005 96 : 791 5
17. Millikan R, Baez L, Banerjee T et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol 2001 6 : 111 5
18. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997 57 : 1204 7
19. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004 22 : 1025 33
20. Small EJ, Halabi S, Picus J, Chen Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Am Soc Clin Oncol 2001 20 (Suppl.): Abstract 695
21. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993 149 : 607 9
22. Chang SS, Benson MC, Campbell SC et al. Society of Urologic oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005 103 : 11 21
23. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993 71 : 1098 109
24. Atkins JN, Muss HB, Case LD, Richards F, Grote T, McFarland J. Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1996 19 : 23 5
25. Berlin JD, Propert KJ, Trump D et al. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am J Clin Oncol 1998 21 : 171 6
26. Huan SD, Aitken SE, Stewart DJ. 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study. Ann Oncol 1994 5 : 644 5
27. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the treatment of hormone refractory prostate cancer. Cancer 1994 74 : 100 3
28. Kuzel TM, Tallman MS, Shevrin D et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center study. Cancer 1993 72 : 1965 8
29. Morant R, Bernhard J, Maibach R et al. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000 11 : 183 8
30. Rajagopalan K, Peereboom D, Budd GT et al. Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer. Invest New Drugs 1998 16 : 255 8
31. Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest New Drugs 1998 16 : 353 9
32. Schmid HP, Maibach R, Bernhard J et al. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer 1997 79 : 1703 9
33. Smith DC, Jodrell DI, Egorin MJ et al. Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemother Pharmacol 1993 31 : 363 8
34. Van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schroder FH, Mickisch GH. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2000 45 : 509 12
35. Williamson SK, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, Crawford ED. Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Am J Clin Oncol 1996 19 : 368 70
36. Witte RS, Yeap BY, Trump DL. Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial. Invest New Drugs 1994 12 : 255 8
37. Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, Larrimer NR. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group study. Eur J Cancer 1992 28 : 477 8
38. de Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone refractory metastatic prostatic cancer. Urology 1988 31 : 312 7
39. Iversen P, Rasmussen F, Asmussen C et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer. DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 1997 157 : 929 34
40. Loening SA, Beckley S, Brady MF et al. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983 129 : 1001 6
41. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999 17 : 2506 13
42. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996 14 : 1756 64
43. Friedland D, Cohen J, Miller R Jr et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999 26 (Suppl. 17 19 23
44. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999 26 (Suppl. 17 14 8
45. Gravis G, Bladou F, Salem N et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003 98 : 1627 34
46. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001 28 (Suppl. 15 8 15
47. Petrylak D, Shelton G, England-Owens C et al. Response and preliminary survival of a phase II study of docetaxel and estramustine in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2000 19 (Suppl. 334a, Abstract 1312
48. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002 94 : 1457 65
49. Ohlmann CH, Breitenbach K, Pfister D, Engelmann U, Heidenreich A. Docetaxel (DOC.) and Mitoxantrone (MIT) in the Management of Hormone Refractory Prostate Cancer (HRPCA). ASCO Prostate Cancer Symposium 2007 : Abstract 242
50. Hudes GR, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997 15 : 3156 63
51. Vaughn DJ, Brown AW Harker WG et al. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer 2004 100 : 746 50
52. Solit DB, Morris M, Slovin S et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003 98 : 1842 8
53. Kelly WK, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 19 : 44 53
54. Segawa T, Kamoto T, Kinoshita H et al. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. Int J Clin Oncol 2005 10 : 333 7
55. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999 17 : 1664 71
56. Berthold DR, Pond G, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Updated survival of the TAX 327 study. J Clin Oncol 2008 26 : 242 5
57. National Comprehensive Cancer Network. NCCN Guidelines for the Treatment of Prostate Cancer. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/prostate.pdf. Accessed January 2007
58. Heidenreich A, Aus G, Abbou CC et al. Guidelines on Prostate Cancer. Eur Assoc Urol 2007. Available at: http://www.galil-medical.com/files/07%20EAU- Prostate%20Cancer(1).pdf. Accessed April 2007
59. Kataja VV, Vergh J. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 2005 16 (Suppl. 1 i34 6
60. Chang SS, Benson MC, Campbell SC et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate cancer. Cancer 2005 103 : 11 21
61. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007 25 : 669 74
62. Novacea halts late-stage trial of prostate cancer drug Asentar. Press release. November 5, 2007. Available at: http://www.fiercebioTechnicalcom/press- releases/press-release-novacea-halts-late-stage-trial-prostate-cancer-drug- asentar. Accessed January 2008
63. Vaishampayan UN, Santucci R, Heilbrun L et al. Phase II trial of docetaxel and capecitabine combination in metastatic androgen independent prostate cancer (AIPC). ASCO Prostate Cancer Symposium 2007 Abstract 239
64. Kolodziej M, Neubauer MA, Rousey SR et al. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006 5 : 155 61
65. Ferrero JM, Chamorey E, Oudard S et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006 107 : 738 45
66. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42
67. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 34
68. Picus J, Halabi S, Rini B et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003 22 (Suppl.): Abstract 1578
69. Nelson JB. Endothelin receptor antagonists. World J Urol 2005 23 : 19 27
70. Salimichokami M. Combining angiogenesis with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer: a randomized study of weekly docetaxel alone or in combination with thalidomide. J Clin Oncol 2003 22 (Suppl.): Abstract 1725
71. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004 22 : 2532 9
72. Ning YM, Gulle J, Arlen P et al. Phase II trial of thalidomide, bevacizumab and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). ASCO Prostate Cancer Symposium 2007 Abstract 228
73. Carducci M, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007 110 : 1959 66
74. Bagnato A, Cirilli A, Salani D et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002 62 : 6381 4
75. Rosano L, Spinella F, Salani D et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003 63 : 2447 53
76. Sternberg CN, Hetherington J, Paluchowska B et al. Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2003 22 (Suppl.): Abstract 1586
77. Sternberg CN, Petrylak D, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC. Results of a randomized phase III trial. J Clin Oncol 2007 25 (Suppl.): Abstract 5019
78. Anonymous. Satraplatin pivotal phase III trial fails to meet primary endpoint. Oncol News Int 2007 16. Available at: http://www.cancernetwork.com/ showArticle.jhtml?articleId=203102743 Accessed January 2008
79. Eymard J, Oudard S, Gravis G et al. Second-line chemotherapy with docetaxel in men treated with docetaxel-based regimens for metastatic hormone-refractory prostate cancer (mHRPC). ASCO Prostate Cancer Symposium 2007 : Abstract 249
80. Oh WK, Manola JM, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone-refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006 67 : 1235 40
81. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006 6 : 1163 7
82. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006 24 : 3089 94
83. Beer TM, Bernstein GT, Corman JM et al. Randomized trial of active cellular immunity with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol 2007 25 (Suppl.): Abstract 5059
84. Tolcher AW, Chi K, Kuhn J et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate. Cancer Clin Cancer Res 2005 11 : 3854 61
85. Sternberg CN, Dumez H, Van Poppel H et al. Multicenter randomized EORTC Trial 30021 of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC). ASCO Prostate Cancer Symposium 2007 Abstract 144
86. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74
87. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002 95 : 281 6
88. Glode LM, Hussain MH, Benson MC et al. SWOG 9921 - a phase III multi-institutional trial of adjuvant therapy for high risk prostate cancer after radical prostatectomy. ASCO Prostate Cancer Symposium 2007 : Abstract 349
89. Flaig TW, Tangen CM, Hussain MHA et al. Michael Glodé randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008 26 : 1532 6
90. Kibel AS, Rosenbaum E, Kattan MW et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007 177 : 1777 81
91. Oh WK. High-risk localized prostate cancer: integrating chemotherapy. Oncologist 2005 10 (Suppl. 1 18 22
92. Sandler H, DeSilvio M, Pienta KJ et al. Preliminary analysis of RTOG 9902: increased toxicity observed with the use of adjuvant chemotherapy. ASCO Prostate Cancer Symposium 2006 Abstract 190
93. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005 11 : 5233 40
94. Dreicer R, Magi-Galluzz C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004 63 : 1138 42
95. Pettaway CA, Pisters LL, Troncoso P et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000 18 : 1050 7
96. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001 57 : 281 2
97. Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003 62 (Suppl. 1 55 62